A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

Brief description of study

The purpose of the study is to determine if poziotinib helps to treat advanced cancer by targeting treatment of the EGFR or HER2 Mutation-Positive cells or other EGFR or HER2 activating mutations. In other words, the study is investigating whether poziotinib is effective, safe, and well-tolerated in treating such cancers. This study is for an investigational study drug called poziotinib for the treatment for EGFR or HER2 activating mutations in advanced cancer. Poziotinib is a new type of treatment and is considered investigational. “Investigational” means that it has not yet been approved by the U.S. Food and Drug Administration (FDA) because we and FDA do not know enough about the benefits or side effects of poziotinib in the treatment for EGFR or HER2 activating mutations in advanced cancer.


Clinical Study Identifier: s19-01639
ClinicalTrials.gov Identifier: NCT04172597
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.